Methoxetamine: Difference between revisions
GrimReaper (talk | contribs) No edit summary |
GrimReaper (talk | contribs) No edit summary |
||
| Line 1: | Line 1: | ||
= General Information = | = General Information = | ||
Methoxamine (3-MeO-2-Oxo-PCE) is a near chemical analogue of Ketamine and PCP. It was first publicly reported in 2010. Some say it's similar to Ketamine or a high dose DXM. It has been shown to act as an NMDA receptor antagonist and Serotonin Reuptake Inhibitor. The N-Ethyl group on this compound increases potency. | Methoxamine (3-MeO-2-Oxo-PCE) is a near chemical analogue of Ketamine and PCP. It was first publicly reported in 2010. Some say it's similar to Ketamine or a high dose DXM. Methoxetamine differs from many dissociatives such as ketamine and phencyclidine that were developed as pharmaceuticals in that it was designed for grey market distribution, making it a rare instance of a true designer drug. It has been shown to act as an NMDA receptor antagonist and unlike ketamine also acts as Serotonin Reuptake Inhibitor. The N-Ethyl group on this compound increases potency. | ||
= Dosage = | = Dosage = | ||
| Line 55: | Line 55: | ||
After effects (depends on dose): 2-48 hours | After effects (depends on dose): 2-48 hours | ||
= Effects = | |||
== Positive == | |||
* Euphoria, mood lift | |||
* Sense of calm and serenity | |||
* Vivid recall of past memories and dreams | |||
* Closed- and open-eye visuals (common) | |||
* Out-of-body experience (less intense then ketamine) | |||
= Neutral = | |||
Distortion or loss of sensory perceptions (common) | |||
Dissociation of mind from body | |||
Sweating | |||
Analgesia, numbness | |||
Significant change in perception of time | |||
Increase in heart rate | |||
Confusion, disorientation | |||
= Negative = | |||
* Risk of psychological dependency | |||
* Nasal discomfort upon insufflation | |||
* Blacking out and forgetting one has taken a drug | |||
* Discomfort, pain or numbness at injection site (with IM) | |||
* Severe confusion, disorganised thinking | |||
* Vertigo, spinning sensation (risk of injury) | |||
* Nausea, vomiting | |||
* Susceptibility to accidents (from uncoordination and change in perception of body and time) | |||
* Severe dissociation, depersonalisation | |||
* Loss of consciousness | |||
* Depression of heart rate and respiration (risk increases with increased dose or when combined with depressants) | |||
= Harm Reduction = | = Harm Reduction = | ||
Revision as of 04:52, 9 July 2014
General Information
Methoxamine (3-MeO-2-Oxo-PCE) is a near chemical analogue of Ketamine and PCP. It was first publicly reported in 2010. Some say it's similar to Ketamine or a high dose DXM. Methoxetamine differs from many dissociatives such as ketamine and phencyclidine that were developed as pharmaceuticals in that it was designed for grey market distribution, making it a rare instance of a true designer drug. It has been shown to act as an NMDA receptor antagonist and unlike ketamine also acts as Serotonin Reuptake Inhibitor. The N-Ethyl group on this compound increases potency.
Dosage
Oral
Threshold: 5-20mg
Low: 10-30mg
Common: 40-60mg
Strong: 50-100mg+
Insufflated
Threshold: 5-15mg
Low: 15-30mg
Medium: 30-50mg
Strong: 50-75mg
Hole: 75-100mg+
Sublingual
Threshold: 5-10mg
Low: 10-25mg
Medium: 40-60mg
Strong: 60-75mg
Hole: 75-100mg
Duration
Oral
Onset: 30-60 minutes
Total duration: 3-6 hours
After effects (depends on dose): 2-48 hours
Insufflated
Onst: 5-20 minutes
Total duration: 3-6 hours
After effects (depends on dose): 2-48 hours
Sublingual
Onset: 15-45 minutes
Total duration: 3-6 hours
After effects (depends on dose): 2-48 hours
Effects
Positive
- Euphoria, mood lift
- Sense of calm and serenity
- Vivid recall of past memories and dreams
- Closed- and open-eye visuals (common)
- Out-of-body experience (less intense then ketamine)
Neutral
Distortion or loss of sensory perceptions (common) Dissociation of mind from body Sweating Analgesia, numbness Significant change in perception of time Increase in heart rate Confusion, disorientation
Negative
- Risk of psychological dependency
- Nasal discomfort upon insufflation
- Blacking out and forgetting one has taken a drug
- Discomfort, pain or numbness at injection site (with IM)
- Severe confusion, disorganised thinking
- Vertigo, spinning sensation (risk of injury)
- Nausea, vomiting
- Susceptibility to accidents (from uncoordination and change in perception of body and time)
- Severe dissociation, depersonalisation
- Loss of consciousness
- Depression of heart rate and respiration (risk increases with increased dose or when combined with depressants)
Harm Reduction
- Avoid driving at all costs.
- Avoid walking or moving around in general if you are on a medium to hole dose.
- Taking this on a non-empty substance could lead to nausea.